

Published in final edited form as:

Nat Methods. 2010 October ; 7(10): 837–842. doi:10.1038/nmeth.1504.

A Quantitative Targeted Proteomics Approach to Validate Predicted microRNA Targets in *C. elegans*

Marko Jovanovic^{1,2,3,12}, Lukas Reiter^{1,2,3,10,12}, Paola Picotti⁴, Vinzenz Lange^{4,5,11}, Erica Bogan^{1,2}, Benjamin A. Hurschler⁶, Cherie Blenkiron^{7,8}, Nicolas J. Lehrbach^{7,8}, Xavier C. Ding⁶, Manuel Weiss^{1,2,3}, Sabine P. Schimpf^{1,3}, Eric A. Miska^{7,8}, Helge Grosshans⁶, Ruedi Aebersold^{4,5,9,*}, and Michael O. Hengartner^{1,3,*}

¹Institute of Molecular Biology, University of Zurich, Zurich, Switzerland ²PhD Program in Molecular Life Sciences Zurich, Zurich, Switzerland ³Quantitative Model Organism Proteomics (Q-MOP), University of Zurich, Zurich, Switzerland ⁴Institute of Molecular Systems Biology, ETH Zurich, Zurich, Switzerland ⁵Competence Center for Systems Physiology and Metabolic Diseases, Zurich, Switzerland ⁶Friedrich Miescher Institute for Biomedical Research (FMI), Basel, Switzerland ⁷Department of Biochemistry, University of Cambridge, Cambridge, CB2 1GA, United Kingdom ⁸Wellcome Trust/Cancer Research UK Gurdon Institute, University of Cambridge, Cambridge, CB2 1QN, United Kingdom ⁹Faculty of Science, University of Zurich, Zurich, Switzerland

Abstract

Computational prediction methods for the identification of microRNA (miRNA) target genes benefit from efficient experimental validation strategies. Here we present a large-scale targeted proteomics approach to validate such predicted miRNA targets in *Caenorhabditis elegans*. Using selected reaction monitoring (SRM), we quantified 161 proteins of interest in extracts from wild-type and *let-7* mutant worms. We demonstrate by independent experimental downstream analyses such as genetic interaction, as well as exemplarily performed polysomal profiling and luciferase assays, that validation by targeted proteomics significantly enriches for biologically relevant *let-7* interactors. For example, we show that the zinc finger protein ZTF-7 is a *bona fide let-7* miRNA target. We also validated a set of predicted miR-58 targets, demonstrating that this approach is adaptable to multiple miRNAs of interest. We propose that targeted mass spectrometry can be applied generally to validate candidate lists generated by computational methods or by large-scale experiments, and that the described strategy can easily be adapted to other organisms.

Keywords

targeted proteomics; microRNA targets; *let-7*; *C. elegans*; selected / multiple reaction monitoring; SRM / MRM

*Corresponding Authors: Michael O. Hengartner michael.hengartner@imls.uzh.ch Ruedi Aebersold aebersold@imsb.biol.ethz.ch.

¹⁰present address: Biognosys AG, Zurich, Switzerland

¹¹present address: DKMS Life Science Lab, Dresden, Germany

¹²contributed equally

AUTHOR CONTRIBUTIONS M.J., L.R., M.O.H. and R.A. designed the experiments and wrote the paper. L.R. and M.J. did the majority of the data analysis. M.J. did the majority of the experiments. P.P. and V.L. contributed to and supervised the SRM experiments. E.B. contributed to the RNAi and RT-qPCR experiments. B.A.H. and X.C.D. performed the polysomal profiling experiments. C.B. and N.J.L. contributed to the reporter assays. S.P.S. and M.W. provided the *C. elegans* proteome atlas. H.G. and E.A.M. provided critical input on the manuscript, contributed significantly to the experimental design and the data analysis. M.O.H. and R.A. supervised the whole project.

INTRODUCTION

miRNAs are short non-coding RNAs that bind to target mRNAs and negatively regulate gene expression. miRNAs play important roles in many developmental and disease-related processes¹. A full understanding of miRNA function requires knowledge of their target mRNAs. In recent years much progress has been made experimentally and computationally to identify miRNA targets. Indeed, one of the most widely used approaches to identify potential miRNA targets is to apply different target prediction algorithms¹. However, the many algorithms available predict target sets with only limited overlap and cumulatively identify several hundred potential target mRNAs per miRNA. In addition, large-scale experiments undertaken to identify target mRNAs, such as studies based on mRNA profiling, pulldown of target mRNAs and to a certain extent on genetics also identified a large number of potential miRNA targets^{2,3}. Recent publications have clearly shown that using multiple independent experimental approaches greatly improves the reliability of the results obtained^{4,5}. Unfortunately, large-scale experiments are often cumbersome and time intensive. Therefore we aimed to establish a targeted quantification method to rapidly validate large numbers of potential miRNA targets.

We reasoned that such a method should measure the most relevant output of gene expression, namely miRNA dependent changes in protein levels of the potential target genes. Moreover, in order to be worthwhile, the method should be easy to use, fast, sensitive, reproducible, quantitative and scalable, as several hundred proteins have to be tested for each miRNA. A technique that promises to fulfill most of those criteria is proteomics. Indeed several groups have shown that shotgun proteomics can be successfully applied to screen for miRNA targets^{4,6}. However, with available shotgun proteomics approaches, the bulk of measurement time is spent on signals not arising from the desired candidate proteins. Moreover, many of the desired proteins might not be measured due to the stochastic sampling of the peptide ions that is common to this method. This results in loss of sensitivity and reproducibility to a degree that high confidence data on candidate targets can only be achieved at a high cost of time and labor. In contrast, a targeted proteomics approach such as selected reaction monitoring (SRM)^{7,8} has the potential for fast and reliable protein quantification of candidate genes: By limiting the measurement to the proteins of interest, the sensitivity and the reproducibility of the measurements increase dramatically. This can be achieved by selecting for each candidate miRNA target protein one or several proteotypic peptides (PTPs) - peptides that unambiguously identify a protein of interest and have favorable detection properties by mass spectrometry⁹.

Here, we describe the application of SRM-based targeted proteomics and isotope-coded affinity tag (ICAT)¹⁰ quantification to screen scores of potential *let-7* targets in *C. elegans*. Our targeted proteomics approach provided high confidence quantification data, which we then mined to identify potential miRNA targets of biological significance. Independent downstream experiments, including genetic studies, exemplary polysomal profiling and luciferase assays, confirmed that the candidate genes classified as regulated by *let-7* based on our protein quantification data are indeed enriched in *let-7* interactors. In addition, we showed that the described method is easily adaptable to other miRNAs of interest and quantification strategies than ICAT, such as metabolically labeled worms. Based on this proof of principle study, we suggest that SRM-based targeted proteomics can be widely used to screen candidate lists generated by computational methods and/or by large-scale experiments.

RESULTS

SRM-based validation of potential *let-7* target genes

To quantify proteins of interest in a complex whole worm extract generated from *C. elegans*, we developed a protocol combining ICAT sample labeling and SRM mass spectrometry (SRM/ICAT; see Supplementary Fig. 1 and Supplementary Data 1). To test the utility of this new protocol, we applied it to screen through a set of several hundred potential *let-7* miRNA targets. We focused on *let-7* because it is highly conserved from *C. elegans* to humans¹¹ and is one of the best studied nematode miRNAs¹². We used for our studies the hypomorphic allele *let-7(n2853)*, which contains a point mutation within the mature *let-7* seed sequence that also results in a reduction in *let-7* expression levels¹³.

The experimental strategy used to quantify potential *let-7* targets is described in Figure 1. We developed SRM assays for 181 candidate proteins (from an original list of 861 proteins, including candidates and controls; Fig. 1), and measured the relative abundance changes of these proteins in synchronized *let-7(n2853)* mutants and wild-type late L4 larvae (when *let-7* miRNA expression is the highest) in three biological replicates. Most target proteins (139) could be quantified in all three biological replicates, another 15 in two replicates and 7 in one replicate, yielding quantification data for a majority of the identified proteins (161 out of 181; 89 %) and confirming the high reproducibility of this method (Fig. 2a and Supplementary Table 2). The normalized log₂ ratios (*let-7(n2853)* versus wild type) and corresponding *P*-values for all 161 proteins that we quantified are shown in Figure 2b and listed in Supplementary Table 2.

Twenty nine proteins showed a significant difference in expression level ($P < 0.01$, one sample Student's *t*-test; Fig. 2c and Supplementary Table 3): 10 proteins were down- and 19 proteins upregulated in *let-7(n2853)* worms. As expected, the two control genes *vit-2* and *vit-6*, which show a greatly reduced abundance at the mRNA level in *let-7(n2853)* mutants (Hirschler B *et al.*, unpublished data) were also strongly downregulated in our assay (13-fold and 23-fold respectively; Supplementary Table 3). The upregulated protein set included LET-526 (also known as LSS-4), the only previously reported *let-7* target¹⁴ whose abundance we could measure. Interestingly, our SRM measurements suggest that the two splice-variants of LET-526 respond differently to *let-7*: whereas a peptide specific for the LET-526a splice form showed a strong, 3.1-fold change, a second peptide, matching to a region common to both splice-isoforms, displayed only a weak 1.2-fold upregulation in *let-7(n2853)* mutant worms (see Supplementary Fig. 2a and b). We confirmed and validated this splice-variant specific response by polysomal profiling (see Supplementary Fig. 2c and Supplementary Data 2).

Also among the significantly changed proteins were 15 of the 66 predicted *let-7* targets based on bioinformatics, and 9 out of 53 proteins whose mRNA do not contain a predicted *let-7* target site, but that have been linked to *let-7* through other experimental approaches or the literature (Supplementary Table 3). By contrast, only 2 out of 39 of the randomly picked “neutral controls” showed a significant abundance change. Interestingly the “neutral controls” were the only significantly underrepresented group among the regulated proteins ($P = 0.016$, Fisher's Exact Test). This low “hit rate” for these randomly tested proteins confirms that our initial candidate list was indeed enriched for *let-7* miRNA target genes.

Whether the regulated candidates are primary or secondary targets of *let-7* cannot be determined from the protein ratios. Although the most straightforward explanation for proteins downregulated in *let-7(n2853)* mutants is secondary effects, as it is the case for the two control proteins VIT-2 and VIT-6 (Hirschler B *et al.*, unpublished data), miRNAs have recently been reported to act as positive regulators under certain conditions¹⁵. A gain-of-

function caused by the point mutation within the seed region of the mature *let-7* miRNA in *let-7(n2853)* mutants, resulting in better binding to a suboptimal seed sequence, also cannot be excluded at this point.

SRM-based validation enriches for *let-7* genetic interactors

let-7(n2853) mutant worms grown at 25°C die at the adult stage due to vulval bursting. Knockdown by RNAi of known *let-7* miRNA targets has been shown in some cases to rescue this lethality to different extents¹⁴. To determine whether the positive hits in our proteomics screen are indeed enriched in *let-7* targets, we knocked-down all 29 genes that showed protein changes in *let-7(n2853)* mutants (up- or downregulated) to determine whether they could suppress the *let-7(n2853)* lethal phenotype. Knock-down of ten genes successfully and reproducibly rescued the lethality to at least 20 % (Fig. 3a and Supplementary Table 4). As expected, the vast majority (9/10) of the suppressors were genes that were upregulated in *let-7(n2853)* mutants (and whose overexpression could thus be compensated via RNAi knock-down). As a control, we performed a similar experiment using 29 candidate genes that did not show significant protein changes in our targeted proteomics assay. Only three genes from this set were able to rescue the lethality (Fig. 3b and Supplementary Table 5), demonstrating that the regulated protein set is significantly enriched for genes that genetically interact with *let-7* ($P = 0.024$ for all regulated genes, $P = 0.013$ considering only the upregulated genes, Fischer's Exact Test; Supplementary Fig. 3). We conclude that a targeted proteomics method can indeed be used to enrich for miRNA interaction partners from a list of candidate genes.

Partial correlation between protein and mRNA abundances

In addition to causing translational repression, miRNAs can also lead to degradation of their targets¹. To determine whether the changes in protein levels that we observed could also be captured at the mRNA level, we determined transcript levels for all 161 proteins, as well as for the well established *let-7* targets *daf-12* and *lin-41*, in wild-type and *let-7(n2853)* worms (Supplementary Table 6). Both *daf-12* and *lin-41* mRNA levels were significantly upregulated in *let-7(n2853)* mutants ($P = 0.006$ and 0.048 , respectively, one-sided one sample Student's t-test), as has been reported previously^{16,17}. Interestingly, while some proteins showed a very good correlation between mRNA and protein changes, others, including the known *let-7* target *let-526*, showed a significant protein change but no strong change in mRNA levels (Fig. 4a). As our targeted proteomics method cannot distinguish primary from secondary targets, we do not know at this point whether the proteins that show strong protein changes but no mRNA changes are primary *let-7* targets.

We next focused our attention on the 47 genes that we previously tested for suppression of *let-7(n2853)* lethality (see above). Whereas many of the 13 RNAi suppressors showed large changes in protein levels in *let-7(n2853)* mutants, their mRNA levels varied only weakly if at all (Fig. 4b). We conclude that many of the protein changes we detected in our targeted proteomics approach are not recapitulated on the mRNA level, and that while mRNA profiling can identify a large number of primary targets^{4,5}, it would fail to detect several of the biologically important candidates revealed by protein quantification.

The zinc finger protein ZTF-7 is a *bona fide let-7* target

One of the most interesting candidates from our RNAi screen was *ztf-7* (F46B6.7), as knockdown of this gene not only suppressed lethality (see Fig. 3 and Supplementary Table 4), but also the sterility observed in *let-7(n2853)* mutants at 25 °C (data not shown). Of the genes that we tested, only the two positive controls *daf-12* and *lin-41* could also suppress both defects. Consistent with our RNAi results, lethality was strongly reduced in

ztf-7(tm600); let-7(n2853) double mutant worms when compared to the *let-7(n2853)* single mutants (Fig. 5a).

Our targeted proteomics measurements had indicated that ZTF-7 protein levels are elevated by ~ 10 % in *let-7(n2853)* mutants when compared to wild-type worms. Although this increase is admittedly mild, it was reproducible across all three biological replicates and highly significant ($P = 0.005$, one sample Student's t-test; see Supplementary Table 3).

As *ztf-7* is predicted to contain a conserved perfect seed complementary *let-7* binding site in its 3' UTR^{18,19} we next tested whether the *ztf-7* 3' UTR is able to confer *let-7* dependent regulation of a reporter transcript. It has been reported that certain *C. elegans* 3' UTRs can elicit a miRNA dependent response in human cell lines²⁰. As the sequence of the mature *let-7* miRNA is identical in *C. elegans* and in humans¹¹, we could rapidly test the effect of both overexpression and depletion of human *let-7a* miRNA in HeLa cells, which were transfected with a dual luciferase plasmid where the *ztf-7* 3' UTR was cloned directly downstream of the firefly luciferase gene (luciferase::*ztf-7* 3' UTR). Indeed, we observed a strong response of the luciferase::*ztf-7* 3' UTR reporter to both human *let-7a* up- and downregulation (Fig. 5b).

Taken together, our proteomics, genetic and reporter assays strongly suggest that *ztf-7* is a *bona fide let-7* miRNA target. Moreover, *ztf-7* was also identified recently as a potential *let-7* target by novel approach²¹, thus providing independent support for our claim that *ztf-7* is a *bona fide let-7* target. Additionally that method also allowed to map the binding site, which overlapped perfectly with the predicted conserved seed site. Further work will be required to understand the function of ZTF-7 in *C. elegans* development.

A streamlined pipeline for miRNA target validation

To test the generality of our targeted proteomics approach, we performed a second experiment in which we aimed to validate predicted targets of miR-58. *mir-58* is of particular interest as it is part of a miRNA gene family. Whereas the single mutants show no obvious defect, the whole family knock out is severely sick²². Therefore, it was unclear whether predicted miR-58 targets would already show significant changes in single mutants.

We took advantage of this second experiment to introduce several technical improvements. First, to target the full peptide repertoire of *C. elegans* and not just cysteine-containing peptides, we used metabolically heavy isotope-labeled worms²³ as a quantification standard. Second, we used crude chemically synthesized peptides to establish and optimize the SRM assays²⁴. Third, we applied a newly developed algorithm that automatically assigns peak groups to their corresponding peptides and controls the false discovery rate (FDR) of those assignments (Reiter L., Rinner O. *et al.*, manuscript submitted).

The TargetScan^{18,19} program predicts 118 miR-58 target genes in *C. elegans*. To validate this candidate list, we ordered crude synthetic peptides for all 118 proteins and used them to develop and optimize SRM assays. We also developed SRM assays for a set of 42 "neutral control" genes that were randomly selected from a set of 5000 genes that are well expressed in L4 hermaphrodites (data not shown). We next measured as many of these proteins as possible directly in complex, unfractionated extracts derived from staged L4 wild-type and *mir-58(n4640)* mutant worms. Applying a 5% FDR cutoff for the correct peak assignment, we could quantify 27 out of the 118 predicted targets and 24 out of the 42 randomly chosen proteins in at least one replicate pair (Supplementary Table 7). We found that predicted miR-58 targets were, as a group, significantly more likely to be upregulated in *mir-58(n4640)* mutant worms when compared to the randomly chosen control group (Fig. 6; $P < 10^{-3}$, Kolmogorov-Smirnov (KS) test). Consistent with this observation, we found that 4

out of 27 predicted targets, compared to 1 out of 24 control proteins, were significantly upregulated in *mir-58(n4640)* mutant worms ($P < 0.05$, one-sided one sample Student's *t*-test; Supplementary Table 7)

miR-58 is a member of a highly abundant miRNA family that also includes miR-80, miR-81, miR-82, and the recently discovered miR-1834²². As expected, TargetScan predicts largely overlapping sets of targets for the various miR-58 family members. Thus, the miR-58 family might show significant redundancy, as loss of a single miRNA might be compensated by the other family members. Consistent with this hypothesis, single *mir-58* family mutants are all overtly wild-type, whereas the *mir-58,80,81,82* quadruple mutant is severely sick. Interestingly, despite this redundancy at the organismal level, we found that targets predicted to be bound by all miR-58 family members (18 out of 27) still showed a significant increase in abundance in *mir-58(n4640)* mutants (Fig. 6; $P < 10^{-3}$, KS test). Analysis of protein levels in the family knock-out will be necessary to determine the exact extent of compensation that does occur, if any, within this miRNA family.

DISCUSSION

Our results demonstrate the suitability and advantages of a targeted proteomics approach to find biologically relevant candidate miRNA targets. First, this method measures changes in protein levels, arguably the most relevant assay for miRNA activity. Second, our approach allows for the quantification of several hundred proteins and thus has a much higher throughput than traditional protein quantification methods such as immunoblotting. Additionally the development of suitable mass spectrometric assays is significantly faster and cheaper than that of immunoassays²⁵. Moreover, once an SRM assay is established for a protein, it becomes universally useful and exportable^{8,26}. Thus, the SRM assays we established for the 312 *C. elegans* proteins that we measured (**Supplementary Table 8 and 9**) can now readily be used by others. Third, because it focuses on highly responsive peptides, our SRM-based approach is highly sensitive and reproducible. Indeed, we could reproducibly measure changes as small as ten percent in total protein abundance, as exemplified with ZTF-7. This high accuracy is particularly important in the analysis of potential miRNA targets, as miRNAs have been shown to mostly induce small changes in target gene expression^{4,6}.

Despite the clear value of our targeted proteomics approach, several challenges remain. First, although we achieved a high sensitivity, we still failed to quantify a substantial fraction of the proteins we had in our target list. Further technical improvements, e.g., combination of chemically synthesized peptides and sample fractionation – could potentially boost the sensitivity by an order of magnitude, as has previously been shown in yeast⁷. Second, the targeted proteomics approach cannot distinguish primary from secondary targets. Additional experiments will thus invariably be necessary to establish which hits are direct targets, as we did for *ztf-7*.

We must also stress that the applicability of our targeted proteomics method to whole organ or whole animals is particularly challenging, as the miRNA of interest might be of low abundance or have a highly restricted expression pattern. We therefore conclude that our method will function best in situations where sufficient material can readily be obtained and the sample is homogenous (e.g., cell lines). For a more in depth discussion of those three limitations please refer to the Supplementary Discussion.

The targeted proteomics approaches described here should be considered complementary to the shotgun proteomics approaches recently reported to identify miRNA targets^{4,6}. While shotgun proteomics should be regarded as one of several discovery tools that can be used to

find potential new miRNA target candidates, a targeted proteomics approach should be perceived as a validation / hypothesis driven tool with high sensitivity, reproducibility and accuracy.

Importantly, while we applied the targeted proteomics method described here for the validation of miRNA targets in *C. elegans*, the method is broadly applicable, and can readily be adapted to other organisms and to other biological questions. A wide range of quantification methods are available²⁷, suitable for nearly every extract composition. In addition, there are public proteomics databases for a wide range of different organisms, where experimentally identified proteins and their corresponding PTPs can be easily mined^{28,29}. Even for organisms where such proteomics data is not readily accessible, sophisticated PTP prediction algorithms⁹ can be consulted in order to target the right peptides. Thus, the targeted proteomics approach described here can be applied generally to measure protein abundances of long candidate lists generated by computational methods or by large-scale experiments.

MATERIALS and METHODS

Mutations

All mutants used in this study were derived from the wild-type variety Bristol strain N2. The following mutations were used: LGV: *ztf-7(tm600)* (see <http://www.wormbase.org>); LGX: *let-7(n2853)*¹³, *ain-1(ku322)*³².

Sample preparation for *let-7* related experiments

C. elegans strains were cultured as described previously³³. All strains were grown at either 15 °C or 25 °C.

C. elegans wild-type strain N2 (Bristol) and the *let-7(n2853)* mutant strain MT7626 were grown on 9-cm nematode growth medium (NGM) agar plates seeded with a lawn of the *E. coli* strain OP50. N2 and *let-7(n2853)* worms were always grown in parallel (3 biological replicates total). Protein extracts were generated from synchronized late L4 larval stage worms (before vulval bursting), which were grown at 25 °C. Worms were harvested and washed three times in M9 media. Generation of the protein extract has been described previously³⁰. The buffer used was 50 mM Tris/HCl (pH 8.3), 5 mM EDTA, 8 M urea and 0.125 % SDS. Cell debris were removed by sequential centrifugation (4000 g for 5 min followed by 16 000 g for 5 min) and the protein concentrations of the purified extracts were determined by using the Bradford reagent (Sigma-Aldrich). The protein concentrations of N2 and *let-7(n2853)* extracts were adjusted to each other in order to minimize biases for the subsequent ICAT (Applied Biosystems) labeling¹⁰.

ICAT labeling, tryptic digestion of the samples, and the isolation and clean up of ICAT labeled cysteine containing peptides were performed as described in Shiio and Aebersold (2006)³⁴. N2 extracts were always labeled with the heavy ICAT reagent and *let-7(n2853)* extracts with the light ICAT reagent. A total of 5 mg per sample and replicate was labeled, resulting in approximately 500 µg ICAT-labeled peptides. The peptide mixtures were cleaned by Sep-Pak tC18 cartridges (Waters) and eluted with 60% acetonitrile. The resulting peptide samples were separated according to the isoelectric point of the peptides by off-gel electrophoresis (OGE)⁷ using a pH 3-10 IPG strip (AmershamBiosciences), and a 3100 OFFGEL Fractionator (AgilentTechnologies) with collection in 24 wells. Prior to electrofocusing, the peptides were evaporated to dryness in a centrifugal vacuum concentrator and solubilized in a separation medium containing 7 M Urea, 2 M thiourea, 1 % w/v DTT, 5 % v/v glycerol, 1 % v/v carrier ampholytes mixture (IPG buffer pH 3.0-10.0, GE Healthcare) loaded in all wells and the potential was fixed at 8000 V with a maximum

current set at 50 μ A. Peptides collected in each well were cleaned by Sep-Pak tC18 cartridges (Waters) and eluted with 60 % acetonitrile. All peptide samples were evaporated in a vacuum centrifuge to dryness, resolubilized in 2 % acetonitrile and 0.1 % formic acid and frozen at -20 °C until analysed on the mass spectrometer.

RT-qPCR

Prior to protein isolation, a small aliquot of intact worms of each biological replicate (three times N2 wild-type worms and three times *let-7(n2853)* worms – see “sample preparation” above) was frozen, and subsequently used for total RNA isolation. Total RNA was isolated using the Nucleo Spin RNA II kit (Marcherey-Nagel) according to the manufacturer’s instructions. After total RNA isolation, genomic DNA was further digested by DNase I using the Turbo DNA-free kit (Ambion) according to the manufacturer’s instructions. Total RNA concentrations were determined with the Nanodrop device (Thermo Fisher Scientific). RNA reverse transcription (RT) was performed using the Transcriptor High Fidelity cDNA Synthesis Kit (Roche) with oligo-(dT) primers, according to the manufacturer’s recommendations using equal amounts of RNA ($4 \times 2 \mu$ g) for each sample. qPCR reactions were performed in technical duplicate for each of the biological triplicates using MESA Green qPCR Mastermix Plus for SYBR Assay (Eurogentec), according to the manufacturer’s recommendations, on an ABI 7900 HT Sequence Detection System coupled to ABI Prism 7900 SDS 2.2 Software (Applied Biosystems). Relative transcript levels were calculated using the $2^{-\Delta C_t}$ method³⁵. Most primer pairs were designed via the Roche Universal Probe Library. All the primer pairs used are listed in Supplementary Table 10.

Polysomal profile analysis and subsequent RT-qPCR

The polysomal profile analysis and subsequent RT-qPCR was performed using the same polysomal fractions and protocols as Ding XC and Grosshans H (2009)¹⁷. The experiments were performed in triplicate.

We could not develop an RT-qPCR assay specific for *let-526b* only, as there is just a small region (< 50bp) in this splice form that is not present in *let-526a*. Instead we used primers specific for both splice forms. The primers used for *let-526a* specifically were 5' accacgaccaccatcatccat3' and 5' cgggcattgtagaagagac3'. The primers for both *let-526a* and *let-526b* were 5' tcgccgagagattactcgtt3' and 5' agaagcgatgcaaagagcat3'

RNAi experiments

Gene knockdown was achieved through RNAi by feeding as published^{36,37,38,39,14}. Media supplement were used at the following concentrations: ampicillin, 200 μ g/ml; isopropyl- β -D-thiogalactopyranoside (IPTG), 2 mM. All the experiments were performed at 25 °C. About 100-150 synchronized L1s were placed on IPTG/AMP NGM agarose plates seeded with 200 μ l *E. coli* expressing double-stranded RNA (dsRNA). The worms were scored 72 hours later (adult stage) for suppression of lethality. Clones were regarded as positive when at least 20 % of the worms were viable as adults. All the clones used were verified by sequencing for their correct insert. All RNAi plasmids used are listed in Supplementary Table 11.

Lethality assays for *C. elegans* mutant strains

All the experiments were performed at 25 °C and in quadruplicate. About 100-150 synchronized L1s were placed on NGM agarose plates seeded with 250 μ l OP50 *E. coli* bacteria. The worms were scored 48 hours later (= 12 hours post L4) for suppression of lethality. Following strains were tested: MT7626 (*let-7(n2853)*), FX00600 (*ztf-7(tm600)*),

WS5673 (*ztf-7(tm600); let-7(n2853)*). At least 20 % of the worms had to be viable in the double mutant worms (WS5673) in order to be regarded as a successful suppressor.

It should be noted that 24 hours post L4 most double mutant worms (WS5673) were dead, therefore suggesting more a lethality delay than a true suppression. A developmental delay in WS5673 worms could be excluded as the survivors at the 12 hours post L4 time point had fully developed gonads with oocytes and at least 60 % of the survivors also had embryos.

Cloning of 3' UTRs from candidate genes

pEM393 is a dual luciferase Gateway (Invitrogen) compatible vector, adapted from the psiCHECK-II vector (Promega). The 3' UTRs of F46B6.7 (*ztf-7*), C12C8.3 (*lin-41*), F11A1.3a (*daf-12*), F13D11.2 (*hbl-1*), F36A4.7 (*ama-1*) and T04C12.6 (*act-1*) were cloned directly downstream of the Firefly Luciferase gene. The 3' UTRome *C. elegans* database⁴⁰ (utrome.org) and Wormbase (www.wormbase.org) were used to retrieve the sequences for the 3' UTRs of interest. Supplementary Table 12 lists the primers used for the PCR reaction and the length of each putative 3' UTR sequence cloned. Gateway cloning was performed according to the manufacturer's instructions (Invitrogen). Briefly, the sequences of interest were amplified using the *attB* adapter primer PCR protocol to generate PCR clones containing the 3' UTR flanked by respective *attB* sites (*attB1* site at the 5' end and the *attB2* site the 3' end). The PCR product was recombined into pDONR221 by the BP reaction to create the entry clone set (see Supplementary Table 12). The entry clones were verified by sequencing and then recombined with the destination vector pEM393 to generate the expression clone set via the LR reaction (see Supplementary Table 12). The expression clones were again verified by sequencing and used for the subsequent luciferase assays.

Luciferase assay

The reactions were performed in 96 well plates. miRNA mimics or inhibitors were ordered from Dharmacon. 150 ng of the dual luciferase expression clone containing the 3' UTR of interest and 10 pmol of either the human *let-7a* mimic, the control mimic (*C. elegans* miR-67), the human *let-7a* inhibitor or the control inhibitor (against *C. elegans* miR-67) were transfected into HeLa cells (10,000 cells per reaction) in triplicate. The Dual-Glo Luciferase assay system (Promega) was used two days post-transfection, according to the manufacturer's instructions. All the firefly luciferase readouts were first normalized to their matching renilla luciferase readouts. Those readouts were further normalized to empty vector (pEM393 vector without any 3' UTR) controls and then the *let-7a* readouts (mimics and inhibitors) were normalized to their respective oligo controls.

Selection of *let-7* candidates

861 genes of interest were selected based on literature, computational prediction algorithms^{41,42,43,14,44}, experimental evidence, published literature, including known *let-7* target genes^{13,14,45,46,47,48,49,50,51} and MS detectability³⁰ (random controls). The predicted targets from the computational prediction algorithms were (1) from miRBase – based on the miRanda prediction algorithm v3.0^{Ref.43}. The *let-7* targets were downloaded on 25/April/2006. A *P*-value cutoff of 0.005 was applied; (2) from Pictar – all *let-7* targets available on the website (http://pictar.mdc-berlin.de/cgi-bin/new_PicTar_nematode.cgi?species=nematode) when download (26/April/2006)⁴¹; (3) our so called “Stark targets” – *let-7* target prediction for *C. elegans* based on the algorithm described in Stark *et al.* (2005)⁴². The target list was provided by Alexander Stark; (4) all the *let-7* targets published in Grosshans *et al.* (2005)¹⁴; (5) all the *let-7* targets published in Watanabe *et al.* (2006)⁴⁴.

Design of SRM assays for *let-7* related experiments

PTPs were selected based on a large shotgun proteomics data set³⁰. This *C. elegans* proteome atlas data set was filtered for a peptide-spectrum match false discovery rate of 0.17 % corresponding to a protein identification false discovery rate of 5 %³¹. Proteotypic peptides needed to contain at least one cysteine¹⁰ and doubly charged peptides with a high number of identifications were preferred. For each peptide, 4 to 8 fragment ions from the y-ion series were computed. Fragment ions (Q3) with an m/z above the peptide ion (Q1) and with a defined minimal distance to the peptide ion were chosen ($m/z_{Q3} - m/z_{Q1} \geq 50$ Thomson). The peptide ion/fragment ion (Q1/ Q3) transitions were used to trigger the acquisition of triple quadrupole (QQQ) MS/MS spectra of the peptides of interest in *C. elegans* whole worm extracts and in off gel electrophoresis (OGE) fractionated samples. Proteotypic peptides for additional 19 proteins not contained in the *C. elegans* proteome atlas were found using SRM triggered MS/MS. For the samples derived from the OGE fractionations, the isoelectric points of the peptides were predicted using BioPerl⁵² and peptides were targeted in the predicted fraction and in the two neighboring fractions if available.

Database search and extraction of optimal SRM transitions for *let-7* related experiments

The data was converted from the raw .wiff to the .mzXML format using the program mzWiff (version 3.5.3, build Apr 16 2008 14:40:24). The MS/MS spectra from the SRM triggered MS/MS experiments were searched against wormpep140 (www.wormbase.org) using Sequest on a Sorcerer machine (Sorcerer™-SEQUENT®, 3.10.4 release) with light ICAT as static modification and heavy ICAT and/or. oxidized methionine as variable modifications. Precursor mass tolerance was set to 1.5 Da and the data were searched fully tryptic with maximal two missed cleavages. The data was filtered with a peptide-spectrum match FDR of 2.5 % using PeptideProphet⁵³. Three transitions for each proteotypic peptide were generated by extracting the three highest fragment ions and the retention time of the peptide from the triple quadrupole MS/MS. All transitions used for quantification in this study are listed in **Supplementary Table 8**.

Mass spectrometry analysis of *let-7* related experiments

All peptide samples were analyzed on a hybrid triple quadrupole/ion trap mass spectrometer (4000QTrap, ABI/MDS-Sciex) equipped with a nanoelectrospray ion source. Chromatographic separations of peptides were performed on a Tempo nano LC system (Applied Biosystems) coupled to a 16 cm fused silica emitter, 75 μm diameter, packed with a Magic C18 AQ 5 μm resin (Michrom BioResources). Peptides were loaded onto a trapping column from a cooled (4 °C) Tempo autosampler and separated with a linear gradient of acetonitrile/water, containing 0.1 % formic acid, at a flow rate of 300 nl/min. A gradient from 5 to 30 % acetonitrile in 30 or 60 minutes was used. Collision energies used for both SRM and MS/MS analyses were calculated according to the formulas: $CE = 0.044 * m/z + 5.5$ or $CE = 0.051 * m/z + 0.5$ (CE, collision energy, m/z, mass-to-charge ratio of the precursor ion) for doubly and triply charged precursor ions, respectively⁷.

In the SRM assays validation phase, the mass spectrometer was operated in SRM mode, triggering acquisition of a full MS/MS spectrum upon detection of an SRM trace (MRM-triggered MS/MS, threshold 200 ion counts). The set of SRM transitions generated as previously described was split into multiple MS-methods and analyzed in several runs. Each SRM acquisition was performed with Q1 and Q3 operated at unit resolution (0.7 m/z half maximum peak width). An average of 60 transitions (dwell time 20 ms/transition) per run was used for the measurements. MS/MS spectra were acquired in enhanced product ion (EPI) mode for the two highest SRM transitions, using dynamic fill time, Q1 resolution low, scan speed 4000 amu/s, m/z range 300-1400.

The complete transition list used for the quantifications is shown in **Supplementary Table 8**. An average of 60 transitions per run was used for the measurements. The quantification measurements were done in the scheduled SRM mode (retention time window: 900 seconds; target scan time: 2 seconds)

Quantitative and statistical analysis of the *let-7* related experiments

Peak height for the transitions associated to the *let-7(n2853)* (light ICAT label) and wild-type (heavy ICAT label) derived peptides were quantified using the software MultiQuant v. 1.1 Beta (Applied Biosystems). Log₂ fold changes were calculated for each transition separately. These values were then normalized using 11 proteotypic peptides (see Supplementary Fig. 1a and Supplementary Fig. 4) on each biological replicate separately. To test for statistically significant abundance changes, a two sided one sample t-test was done on the normalized log₂ fold changes of the transitions grouped according to protein (μ equal to zero). To generate our list of regulated candidates we used a $P = 0.01$ cutoff.

miR-58 related experiments

Details are given in “Supplementary Materials and Methods”

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank R. Ketting (Hubrecht Institute, Utrecht) and B. Tops (Utrecht University, Utrecht) for providing the metabolically labeled *C. elegans* sample. We also thank A. Stark (Research Institute of Molecular Pathology, Vienna) for sharing miRNA target predictions for *C. elegans*. Additionally we thank M. Moser for the assistance with the RT-qPCR assays; B. Roschitzky and B. Gerrits for technical support; H. Rehrauer for statistical support; R. Schlapbach for access to the Functional Genomics Center Zurich; the Hengartner, Aebersold, Grosshans and Miska laboratories, Erich Brunner and the whole Q-MOP team for insightful discussion and comments on the manuscript. This work was funded in part by the University of Zurich Research Priority Program in Systems Biology/Functional Genomics, the Swiss National Science Foundation, the GEBERT RÜF Foundation, SystemsX, the Ernst Hadorn Foundation and the ETH Zurich. M.J. and L.R. were supported by a grant from the Research Foundation of the University of Zurich. M.J. was also supported by a fellowship from the Roche Research Foundation. P.P. is the recipient of a Marie Curie Intra-European fellowship. V.L. was supported by a grant from F. Hoffmann-La Roche Ltd. to the Competence Center for Systems Physiology and Metabolic Diseases. H.G. was supported by the Swiss National Research Foundation, the Novartis Research Foundation and by an ERC Starting Investigator Grant (miRTurn). X.C.D was supported by a Boehringer Ingelheim Funds PhD Student fellowship. C.B., N.J.L and E.A.M. were supported by a Cancer Research UK Programme Grant to E.A.M. We also want to apologize to all the authors in the miRNA and proteomics field who we did not cite due to limited space.

REFERENCES

1. Bartel DP. MicroRNAs: target recognition and regulatory functions. *Cell*. 2009; 136:215–33. [PubMed: 19167326]
2. Lai EC. miRNAs: whys and wherefores of miRNA-mediated regulation. *Curr. Biol*. 2005; 15:R458–460. [PubMed: 15964265]
3. Ørom UA, Lund AH. Experimental identification of microRNA targets. *Gene*. 2010; 451:1–5. [PubMed: 19944134]
4. Baek D, et al. The impact of microRNAs on protein output. *Nature*. 2008; 455:64–71. [PubMed: 18668037]
5. Hendrickson DG, et al. Concordant regulation of translation and mRNA abundance for hundreds of targets of a human microRNA. *PLoS Biol*. 2009; 7:e1000238. [PubMed: 19901979]
6. Selbach M, et al. Widespread changes in protein synthesis induced by microRNAs. *Nature*. 2008; 455:58–63. [PubMed: 18668040]

7. Picotti P, Bodenmiller B, Mueller LN, Domon B, Aebersold R. Full Dynamic Range Proteome Analysis of *S. cerevisiae* by Targeted Proteomics. *Cell*. 2009 doi:10.1016/j.cell.2009.05.051.
8. Picotti P, et al. A database of mass spectrometric assays for the yeast proteome. *Nat Methods*. 2008; 5:913–4. [PubMed: 18974732]
9. Mallick P, et al. Computational prediction of proteotypic peptides for quantitative proteomics. *Nat Biotechnol*. 2007; 25:125–131. [PubMed: 17195840]
10. Gygi SP, et al. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. *Nat Biotechnol*. 1999; 17:994–9. [PubMed: 10504701]
11. Pasquinelli AE, et al. Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. *Nature*. 2000; 408:86–9. [PubMed: 11081512]
12. Bussing I, Slack F, Groshans H. let-7 microRNAs in development, stem cells and cancer. *Trends in Molecular Medicine*. 2008; 14:400–409. [PubMed: 18674967]
13. Reinhart BJ, et al. The 21-nucleotide let-7 RNA regulates developmental timing in *Caenorhabditis elegans*. *Nature*. 2000; 403:901–6. [PubMed: 10706289]
14. Groshans H, Johnson T, Reinert K, Gerstein M, Slack F. The Temporal Patterning MicroRNA Regulates Several Transcription Factors at the Larval to Adult Transition in. *Developmental Cell*. 2005; 8:321–330. [PubMed: 15737928]
15. Vasudevan S, Tong Y, Steitz JA. Switching from repression to activation: microRNAs can up-regulate translation. *Science*. 2007; 318:1931–4. [PubMed: 18048652]
16. Bagga S, et al. Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation. *Cell*. 2005; 122:553–63. [PubMed: 16122423]
17. Ding XC, Grosshans H. Repression of *C. elegans* microRNA targets at the initiation level of translation requires GW182 proteins. *EMBO J*. 2009; 28:213–22. [PubMed: 19131968]
18. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. *Cell*. 2005; 120:15–20. [PubMed: 15652477]
19. Ruby J, et al. Large-Scale Sequencing Reveals 21U-RNAs and Additional MicroRNAs and Endogenous siRNAs in *C. elegans*. *Cell*. 2006; 127:1193–1207. [PubMed: 17174894]
20. Nottrott S, Simard MJ, Richter JD. Human let-7a miRNA blocks protein production on actively translating polyribosomes. *Nat Struct Mol Biol*. 2006; 13:1108–1114. [PubMed: 17128272]
21. Andachi Y. A novel biochemical method to identify target genes of individual microRNAs: Identification of a new *Caenorhabditis elegans* let-7 target. *RNA*. 2008; 14:2440–2451. [PubMed: 18824511]
22. Alvarez-Saavedra E, Horvitz HR. Many Families of *C. elegans* MicroRNAs Are Not Essential for Development or Viability. *Curr Biol*. 2010 doi:10.1016/j.cub.2009.12.051.
23. Krijgsveld J, et al. Metabolic labeling of *C. elegans* and *D. melanogaster* for quantitative proteomics. *Nat Biotechnol*. 2003; 21:927–931. [PubMed: 12858183]
24. Picotti P, et al. High-throughput generation of selected reaction-monitoring assays for proteins and proteomes. *Nat. Methods*. 2010; 7:43–46. [PubMed: 19966807]
25. Picotti P, et al. High-throughput generation of selected reaction-monitoring assays for proteins and proteomes. *Nat. Methods*. 2009 doi:10.1038/nmeth.1408.
26. Addona TA, et al. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. *Nat. Biotechnol*. 2009 doi:10.1038/nbt.1546.
27. Mueller LN, Brusniak M, Mani DR, Aebersold R. An assessment of software solutions for the analysis of mass spectrometry based quantitative proteomics data. *J Proteome Res*. 2008; 7:51–61. [PubMed: 18173218]
28. Brunner E, et al. A high-quality catalog of the *Drosophila melanogaster* proteome. *Nat Biotechnol*. 2007; 25:576–583. [PubMed: 17450130]
29. Baerenfaller K, et al. Genome-scale proteomics reveals *Arabidopsis thaliana* gene models and proteome dynamics. *Science*. 2008; 320:938–41. [PubMed: 18436743]
30. Schrimpf SP, et al. Comparative Functional Analysis of the *Caenorhabditis elegans* and *Drosophila melanogaster* Proteomes. *PLoS Biol*. 2009; 7:e48. [PubMed: 19260763]

31. Reiter L, et al. Protein identification false discovery rates for very large proteomics datasets generated by tandem mass spectrometry. *Mol. Cell Proteomics*. 2009 doi:10.1074/mcp.M900317-MCP200.
32. Ding L, Spencer A, Morita K, Han M. The Developmental Timing Regulator AIN-1 Interacts with miRISCs and May Target the Argonaute Protein ALG-1 to Cytoplasmic P Bodies in. *Molecular Cell*. 2005; 19:437–447. [PubMed: 16109369]
33. Brenner S. The genetics of *Caenorhabditis elegans*. *Genetics*. 1974; 77:71–94. [PubMed: 4366476]
34. Shiio Y, Aebersold R. Quantitative proteome analysis using isotope-coded affinity tags and mass spectrometry. *Nat Protoc*. 2006; 1:139–145. [PubMed: 17406225]
35. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2⁻($\Delta\Delta C_T$) Method. *Methods*. 2001; 25:402–8. [PubMed: 11846609]
36. Fraser AG, et al. Functional genomic analysis of *C. elegans* chromosome I by systematic RNA interference. *Nature*. 2000; 408:325–30. [PubMed: 11099033]
37. Kamath RS, et al. Systematic functional analysis of the *Caenorhabditis elegans* genome using RNAi. *Nature*. 2003; 421:231–7. [PubMed: 12529635]
38. Timmons L, Fire A. Specific interference by ingested dsRNA. *Nature*. 1998; 395:854. [PubMed: 9804418]
39. Rual J, et al. Toward improving *Caenorhabditis elegans* phenome mapping with an ORFeome-based RNAi library. *Genome Res*. 2004; 14:2162–8. [PubMed: 15489339]
40. Mangone M, Macmenamin P, Zegar C, Piano F, Gunsalus KC. UTRome.org: a platform for 3'UTR biology in *C. elegans*. *Nucleic Acids Res*. 2008; 36:D57–62. [PubMed: 17986455]
41. Lall S, et al. A Genome-Wide Map of Conserved MicroRNA Targets in *C. elegans*. *Current Biology*. 2006; 16:460–471. [PubMed: 16458514]
42. Stark A, Brennecke J, Bushati N, Russell R, Cohen S. Animal MicroRNAs Confer Robustness to Gene Expression and Have a Significant Impact on 3'UTR Evolution. *Cell*. 2005; 123:1133–1146. [PubMed: 16337999]
43. Griffiths-Jones S, Saini HK, Dongen SV, Enright AJ. miRBase: tools for microRNA genomics. *Nucleic Acids Research*. 2007; 36:D154–D158. [PubMed: 17991681]
44. Watanabe Y, et al. Computational analysis of microRNA targets in *Caenorhabditis elegans*. *Gene*. 2006; 365:2–10. [PubMed: 16356665]
45. Johnson SM, et al. RAS is regulated by the let-7 microRNA family. *Cell*. 2005; 120:635–47. [PubMed: 15766527]
46. Ding XC, Slack FJ, Grosshans H. The let-7 microRNA interfaces extensively with the translation machinery to regulate cell differentiation. *Cell Cycle*. 2008; 7:3083–90. [PubMed: 18818519]
47. Abrahante JE, et al. The *Caenorhabditis elegans* hunchback-like gene *lin-57/hbl-1* controls developmental time and is regulated by microRNAs. *Dev Cell*. 2003; 4:625–37. [PubMed: 12737799]
48. Slack FJ, et al. The *lin-41* RBCC gene acts in the *C. elegans* heterochronic pathway between the let-7 regulatory RNA and the LIN-29 transcription factor. *Mol Cell*. 2000; 5:659–69. [PubMed: 10882102]
49. Lin S, et al. The *C. elegans* hunchback homolog, *hbl-1*, controls temporal patterning and is a probable microRNA target. *Dev Cell*. 2003; 4:639–50. [PubMed: 12737800]
50. Papadopoulos GL, Reczko M, Simossis VA, Sethupathy P, Hatzigeorgiou AG. The database of experimentally supported targets: a functional update of TarBase. *Nucleic Acids Res*. 2009; 37:D155–8. [PubMed: 18957447]
51. Xiao F, et al. miRecords: an integrated resource for microRNA-target interactions. *Nucleic Acids Res*. 2009; 37:D105–10. [PubMed: 18996891]
52. Stajich JE, et al. The Bioperl toolkit: Perl modules for the life sciences. *Genome Res*. 2002; 12:1611–8. [PubMed: 12368254]
53. Keller A, Eng J, Zhang N, Li X, Aebersold R. A uniform proteomics MS/MS analysis platform utilizing open XML file formats. *Mol Syst Biol*. 2005; 1:2005–0017. [PubMed: 16729052]




Figure 1. Strategy and workflow for targeted protein quantification

(a) General proteomic strategy and (b) workflow for the quantification of potential *C. elegans let-7* interacting genes. (a) A list of potential *let-7* targets was compiled based on predictions from five different algorithms, experimental data (e.g. microarray analysis, RNAi screens, etc.) and the published literature, including known *let-7* target genes. We also included control genes that we knew to be altered in *let-7* mutant worms due to secondary effects (Hirschler B *et al.*, unpublished data) and randomly chosen genes which served as “neutral controls”, resulting in a final list of 861 candidate genes (**Supplementary Table 1**, details in “Material and Methods”). PTPs for these proteins of interest were selected from the *C. elegans* proteome atlas^{30,31}, a recently published large *C. elegans* proteomics dataset, in which 8608 proteins, or about 40% of the proteome was identified by shotgun proteomics experiments. The selected PTPs were used as probes for reproducible quantification by SRM on a QTrap mass spectrometer operated as a triple quadrupole instrument. (b) From the initial set of 861 proteins, 650 had PTPs in the *C. elegans* proteome atlas, of which 391 had cysteine containing peptides and were quantifiable by ICAT. Validated transitions were derived for 181 proteins, of which 161 could be quantified. Of these, 29 proteins showed significant changes in abundance between wild type and *let-7(n2853)* mutants.




Figure 2. Identification of proteins regulated by the *let-7* miRNA

(a) Heat map and hierarchical clustering of the 161 quantified proteins in three separate biological replicates (b.r.1 – b.r.3). Red and blue indicate up- and downregulated proteins in *let-7(n2853)* mutants, respectively (see color code). (b) Volcano plot: normalized mean log₂ ratios and probability of regulation ($-\lg(P\text{-value})$) of the measured proteins. Predicted *let-7* targets (see “Materials and Methods”) are shown in orange, all other proteins in blue. All proteins above the dotted red line (at $P = 0.01$) were considered to be significantly regulated. (c) Heat map and hierarchical clustering of the 29 significantly regulated proteins ($P < 0.01$).




Figure 4. Comparison of *let-7*-dependent changes in protein and transcript levels of candidate *let-7* miRNA targets

log₂ fold changes at the mRNA (x-axis) and protein (y-axis) level between *let-7(n2853)* mutant and wild type worms for (a) all 161 proteins measured and (b) all 47 candidates scored by RNAi. (a) Proteins that are predicted *let-7* targets (see “Materials and Methods”) are shown in orange, all other proteins in blue. (b) Proteins that showed suppression of lethality are shown in red; proteins that did not show suppression of lethality are shown in blue. The error bars indicate the standard error of the mean over the three biological replicates.




Figure 5. ZTF-7 (F46B6.7) is a bona fide *let-7* target

(a) *let-7(n2853)* worms grown at 25°C die at the adult stage due to vulval bursting. Knock-down of some known targets has been shown to rescue this lethality to different degrees¹⁴. 3 % of *let-7(n2853)* mutants are still alive 12 hours post L4. In contrast 43 % of *ztf-7(tm600); let-7(n2853)* double mutants are alive 12 hours post L4. *ztf-7(tm600)* mutants did not show any lethality 12 hours post L4 and no other obvious defects. All the experiments were performed at 25 °C and in quadruplicate. The error bars depict the standard error of the mean. (b) Relative luciferase activities for reporter constructs containing the indicated 3' - UTR sequences. The *let-7a* readouts (mimics and inhibitors) were normalized to their respective oligo controls (see “Materials and Methods” for details). The 3'UTRs of the known targets C12C8.3 (*lin-41*), F11A1.3 (*daf-12*) and F13D11.2 (*hbl-1*) were included as positive controls while the 3'UTRs of F36A4.7 (*ama-1*) and T04C12.6 (*act-1*) were added as negative controls¹⁴. Transfections were performed in triplicate for all candidates but *lin-41* (marked by asterisk (*)), which was only transfected in duplicate. The error bars depict the standard error of the mean.




Figure 6. Predicted miR-58 targets are significantly upregulated in *mir-58(n4640)* mutants
 Comparison cumulative fraction plot of the protein response of predicted miR-58 targets (predicted by TargetScan^{18,19}), also shown divided into miR-58-specific targets and targets bound by all family members and a random gene group upon *mir-58* knockout. Data are shown as log₂ ratios (*mir-58(n4640)* to wild-type). Both the overall group as well as the whole family subgroup are significantly upregulated in *mir-58(n4640)* mutant worms when compared to the proteins that were randomly chosen ($P < 10^{-3}$, Kolmogorov-Smirnov test).